Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$165.79K$165.79Kderived+618.7% vs Q4 2013 Net Income-$802.12K-$802.12KderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$126,839+986.2% Operating Incomederived-$810,789N/M Operating Cash Flowderived-$57,402N/M Free Cash Flowderived-$58,783— Margins · derivedGross margin76.5%+25.9 pt vs Q4 2013
Operating margin-489.0%+4395.4 pt vs Q4 2013
Net margin-483.8%+2176.5 pt vs Q4 2013
ended Dec 31, 2014 · filed Apr 13, 2015 · 103 d after period end